» Articles » PMID: 23788924

The Physical and Chemical Stability of Cisplatin (Teva) in Concentrate and Diluted in Sodium Chloride 0.9%

Overview
Publisher Termedia
Specialty Oncology
Date 2013 Jun 22
PMID 23788924
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Aim Of The Study: The subject of study was the stability of cisplatin in concentrate in glass vials and diluted in polyethylene (PE) bags stored at 15-25°C for up to 30 days.

Material And Methods: Original vials of cisplatin injection (1 mg/ml, Teva) were stored at room temperature and subjected to re-piercing after 1, 2, 3, 7, 14, 21, 28 and 30 days following the initial piercing. Cisplatin infusions at nominal concentrations of 0.1 mg/ml were prepared in 0.9% sodium chloride (1000 ml) in PE bags. Chemical stability was measured by means of a stability-indicating high-performance liquid chromatography (HPLC) assay. Physical stability was assessed by visual inspection in normal light.

Results: The concentration of cisplatin at each sampling time in the analysed solutions remained within 92.0-100.7% of initial concentration, regardless of the container. No changes in colour or turbidity were observed in any of the vials or prepared solutions.

Conclusions: Cisplatin, both undiluted in glass containers and diluted with NaCl 0.9% in PE bags, remains stable (< 10% degradation) for at least 30 days at room temperature when protected from light.

Citing Articles

Status analysis of quality control of administered infusion solution with cytotoxic drugs.

Wang S, Zhang F, Dou X, Pan X, Su C, Tian J Oncol Rev. 2025; 18():1415677.

PMID: 39834531 PMC: 11742943. DOI: 10.3389/or.2024.1415677.


Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process.

Sharma S, Palanikumar L, Pasricha R, Prakasam T, Magzoub M, Jagannathan R Pharmaceutics. 2024; 16(11).

PMID: 39598594 PMC: 11597759. DOI: 10.3390/pharmaceutics16111471.


Enhancing Cisplatin Efficacy with Low Toxicity in Solid Breast Cancer Cells Using pH-Charge-Reversal Sericin-Based Nanocarriers: Development, Characterization, and Biological Assessment.

Bahremand K, Aghaz F, Bahrami K ACS Omega. 2024; 9(12):14017-14032.

PMID: 38560009 PMC: 10976391. DOI: 10.1021/acsomega.3c09361.


Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.

Forgie B, Prakash R, Telleria C Int J Mol Sci. 2022; 23(23).

PMID: 36499737 PMC: 9793759. DOI: 10.3390/ijms232315410.


Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma.

Banella S, Quarta E, Colombo P, Sonvico F, Pagnoni A, Bortolotti F Pharmaceutics. 2021; 13(3).

PMID: 33803276 PMC: 8000699. DOI: 10.3390/pharmaceutics13030362.


References
1.
Cepeda V, Fuertes M, Castilla J, Alonso C, Quevedo C, Perez J . Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007; 7(1):3-18. DOI: 10.2174/187152007779314044. View

2.
Hrubisko M, Mc Gown A, Prendiville J, Radford J, Thatcher N, Fox B . Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. Cancer Chemother Pharmacol. 1992; 29(3):252-5. DOI: 10.1007/BF00686261. View

3.
Miller R, Tadagavadi R, Ramesh G, Reeves W . Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2011; 2(11):2490-518. PMC: 3153174. DOI: 10.3390/toxins2112490. View

4.
Vigneron J, Astier A, Trittler R, Hecq J, Daouphars M, Larsson I . SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr. 2013; 71(6):376-89. DOI: 10.1016/j.pharma.2013.06.002. View

5.
Zieske P, Koberda M, Hines J, Knight C, Sriram R, Raghavan N . Characterization of cisplatin degradation as affected by pH and light. Am J Hosp Pharm. 1991; 48(7):1500-6. View